Context Therapeutics Inc. (CNTX)
NasdaqCM
Fundamentals
Valuation and ratings
Context Therapeutics Inc. trades at USD0.61. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Context Therapeutics Inc.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Super investor ownership
5 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Marshall Wace, MARSHALL WACE, LLP$7.72M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$3.73M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$479.5K · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$366.8K · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$149.9K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own CNTX?
5 of the institutions we track reported a position in CNTX in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
The full research page for CNTX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.